Bank of New York Mellon Corp Buys 72,509 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Bank of New York Mellon Corp raised its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 860.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 80,935 shares of the company’s stock after acquiring an additional 72,509 shares during the quarter. Bank of New York Mellon Corp’s holdings in Dianthus Therapeutics were worth $2,095,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of DNTH. SG Americas Securities LLC bought a new position in Dianthus Therapeutics in the 2nd quarter valued at $112,000. Virtu Financial LLC bought a new position in Dianthus Therapeutics in the 1st quarter valued at $390,000. Hussman Strategic Advisors Inc. bought a new position in Dianthus Therapeutics in the 1st quarter valued at $630,000. StemPoint Capital LP bought a new position in Dianthus Therapeutics in the 1st quarter valued at $1,304,000. Finally, Vestal Point Capital LP bought a new position in Dianthus Therapeutics in the 4th quarter valued at $1,404,000. Institutional investors own 47.53% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on DNTH. Robert W. Baird began coverage on Dianthus Therapeutics in a report on Friday, July 26th. They issued an “outperform” rating and a $58.00 target price for the company. Cantor Fitzgerald began coverage on Dianthus Therapeutics in a report on Thursday, June 27th. They issued an “overweight” rating for the company. Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, August 12th. Finally, Lifesci Capital upgraded Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Dianthus Therapeutics presently has an average rating of “Buy” and a consensus target price of $44.71.

Dianthus Therapeutics Stock Down 1.6 %

Shares of NASDAQ DNTH opened at $25.99 on Wednesday. The firm has a 50-day simple moving average of $28.12 and a 200-day simple moving average of $26.11. The stock has a market capitalization of $762.81 million, a price-to-earnings ratio of -4.46 and a beta of 1.85. Dianthus Therapeutics, Inc. has a 52 week low of $6.58 and a 52 week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. The firm had revenue of $1.86 million during the quarter, compared to analysts’ expectations of $0.63 million. As a group, equities research analysts expect that Dianthus Therapeutics, Inc. will post -2.32 EPS for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.